This year, Ai Mediq had the privilege of participating in the European Society of Cardiology (ESC) Congress held in the city of Amsterdam. This prestigious congress brings together experts from private and public institutions worldwide to exchange knowledge and discoveries in the realm of cardiovascular medicine.
ReOxy therapy and standard rehabilitation has been shown to be as almost twice as effective compared to the standard rehabilitation (83.6 m vs 44.6 m, p<0.001).
The results of the application of ReOxy therapy in patients with osteoarthritis and post-covid syndrome has been demonstrated during the presentation at Eular22
The team led by Prof. Schega from the Department of Health and Physical Activity at the Otto von Guericke University in Magdeburg (Faculty of Human Sciences, Institute III, Sports Sciences) is currently conducting the clinical study “Effects of intermittent hypoxia-hyperoxia on cognitive function, mobility and wellbeing in patients with dementia”
Ai Mediq S.A. is pleased to announce the new stage of scientific cooperation with the Universitätsklinikum Hamburg-Eppendorf (UKE). Together with Dr. Sina Cathérine Rosenkranz we will be looking into potential perspectives of Interval Hypoxic Therapy in the treatment of multiple sclerosis.
Last Friday (26th of July 2019) one of the most recent clinical trials involving ReOxy has been registered with CliniclTrials.gov database with NCT04034082 identifier.
Ai Mediq is pleased to announce approval of new clinical trial named “Evaluation of clinical efficacy of interval hypoxic-hyperoxic trainings in treatment of patients with reduced ejection fraction of left ventricle (2-3 NYHA)
